A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors. (December 2016) - Drilon, A.; Marwan, F.; Fu, S.; Patel, M.R.; Olszanski, A.J.; Lockhart, A.C.; Liu, S.V.; Bazhenova, L.; Seery, T.; Nikolinakos, P.; Patel, R.; Oliver, J.W.; et al.